{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.25","value":"-6.0"},{"groupId":"OG001","spread":"22.60","value":"-9.4"},{"groupId":"OG002","spread":"25.03","value":"-5.8"},{"groupId":"OG003","spread":"23.87","value":"-6.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"}],"units":"Participants"}],"title":"Day 29"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.77","value":"-7.2"},{"groupId":"OG001","spread":"26.09","value":"-8.0"},{"groupId":"OG002","spread":"33.87","value":"-11.0"},{"groupId":"OG003","spread":"26.34","value":"-11.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"}],"units":"Participants"}],"title":"Day 57"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.78","value":"-4.5"},{"groupId":"OG001","spread":"23.08","value":"-12.7"},{"groupId":"OG002","spread":"37.50","value":"-10.5"},{"groupId":"OG003","spread":"28.79","value":"-11.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"}],"units":"Participants"}],"title":"Day 85"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.46","value":"-3.5"},{"groupId":"OG001","spread":"25.03","value":"-13.7"},{"groupId":"OG002","spread":"38.04","value":"-12.3"},{"groupId":"OG003","spread":"29.43","value":"-11.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"}],"units":"Participants"}],"title":"Day 113"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.05","value":"0.7"},{"groupId":"OG001","spread":"25.26","value":"-13.7"},{"groupId":"OG002","spread":"37.33","value":"-15.0"},{"groupId":"OG003","spread":"32.79","value":"-12.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"}],"units":"Participants"}],"title":"Day 141"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.59","value":"-3.0"},{"groupId":"OG001","spread":"24.59","value":"-14.7"},{"groupId":"OG002","spread":"38.40","value":"-15.0"},{"groupId":"OG003","spread":"30.36","value":"-13.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"}],"units":"Participants"}],"title":"Day 169"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"}],"units":"Participants"}],"description":"The visual analog scale (VAS) is a pain rating scale. Scores are based on the percent change from baseline (Day 1) in self-reported measures of symptoms that are recorded with a single handwritten mark placed at one point along the length of a 10-cm line that represents a continuum between the two ends of the scale-\"no pain\" on the left end (0 cm) of the scale and the \"worst pain\" on the right end of the scale (10 cm). Measurements from the starting point (left end) of the scale to the patients' marks are recorded in centimeters and are interpreted as their pain. The values can be used to track pain progression for a patient or to compare pain between patients with similar conditions. In addition to pain, the scale has also been used to evaluate mood, appetite, asthma, dyspepsia, and ambulation.","dispersionType":"Standard Deviation","groups":[{"description":"Placebo was administered within 28 days of screening. Subsequent doses were administered every 28 days for a total of four doses.","id":"OG000","title":"Placebo"},{"description":"0.1 mg/kg administered via subcutaneous injection every 28 days for a total of four doses (i.e., Days 1, 29, 57, and 85), with safety follow-up visits 1 week after each dose (i.e., Days 8, 36, 64, and 92). After completion of the treatment period, participants returned to the study site monthly for follow-up assessments for an additional 3 months (i.e., Days 113, 141, and 169).","id":"OG001","title":"0.1 mg/kg ACE 011"},{"description":"0.3 mg/kg administered via subcutaneous injection every 28 days for a total of four doses (i.e., Days 1, 29, 57, and 85), with safety follow-up visits 1 week after each dose (i.e., Days 8, 36, 64, and 92). After completion of the treatment period, participants returned to the study site monthly for follow-up assessments for an additional 3 months (i.e., Days 113, 141, and 169)","id":"OG002","title":"0.3 mg/kg ACE 011"},{"description":"0.5 mg/kg administered via subcutaneous injection every 28 days for a total of four doses (i.e., Days 1, 29, 57, and 85), with safety follow-up visits 1 week after each dose (i.e., Days 8, 36, 64, and 92). After completion of the treatment period, participants returned to the study site monthly for follow-up assessments for an additional 3 months (i.e., Days 113, 141, and 169).","id":"OG003","title":"0.5 mg/kg ACE 011"}],"paramType":"MEAN","populationDescription":"All treated participants who had at least 1 postdosing measurement","reportingStatus":"POSTED","timeFrame":"From baseline (Day 1) to Day 29, Day 57, Day 85, Day 113, Day 141, Day 169","title":"Percent Change From Baseline in Bone Pain Visual Analog Scale (VAS)","type":"SECONDARY","unitOfMeasure":"Percent change"}